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Abstract  
Objectives: To compare quality of life (QoL) outcomes at 6 months between 
men with advanced prostate cancer (PCa) receiving either transdermal oestradiol 
(tE2) or LHRH agonists (LHRHa) for androgen deprivation therapy (ADT). 
Patients and methods: Men with locally advanced or metastatic PCa 
participating in an ongoing randomised, multi-centre UK trial comparing tE2 
versus LHRHa for ADT were enrolled into a QoL sub-study. tE2 was delivered via 
3 or 4 transcutaneous patches containing 100mcg of oestradiol/24 hours. LHRHa 
was administered as per local practice. Patients completed questionnaires based 
on EORTC QLQ-C30 with prostate-specific module QLQ PR25. The primary 
outcome measure was global QoL score at 6 months, compared between 
randomised arms. 
 
Results: 727 men were enrolled between August 2007 and 5 October 2015 (412 
tE2, 315 LHRHa) with QoL questionnaires completed at both baseline and 6 
months. Baseline clinical characteristics were similar between arms: median age 
74 years (interquartile range [IQR] 68-79), median PSA 44 ng/ml (IQR 19-119), 
and 40% (294/727) had metastatic disease. At 6 months, patients on tE2 
reported higher global QoL than LHRHa (mean difference +4.2, 95% CI 1.2 to 
7.1, p=0.006), less fatigue and improved physical function. Men in the tE2 arm 
were less likely to experience hot flushes (8% vs 46%), and report a lack of 
sexual interest (59% vs 74%) and sexual activity, but had higher rates of 
significant gynecomastia (37% vs 5%). The higher incidence of hot flushes 
among LHRHa patients appear to account for both the reduced global QoL and 
increased fatigue in the LHRHa arm compared to tE2 arm.  
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Conclusion: Patients receiving tE2 for ADT had better 6-month self-reported 
QoL outcomes compared to those on LHRHa, but increased likelihood of 
gynecomastia. The ongoing trial will evaluate clinical efficacy, and longer term 
QoL. These findings are also potentially relevant for short-term neoadjuvant ADT.  
 
Introduction 
Prostate cancer (PCa) is the most frequent cancer diagnosis in men in the 
developed world and responsible for 11,000 deaths per year in the UK and 
26,000 in the US(1, 2). PCa cell growth is driven by androgen signalling, and 
androgen deprivation therapy (ADT) forms a cornerstone of treatment. Evidence 
supports the use of ADT in conjunction with radiotherapy in localised(3, 4) and 
locally-advanced disease(5, 6), and as first-line therapy in the metastatic 
setting(7). 
 
ADT, usually achieved using luteinising hormone-releasing hormone agonists 
(LHRHa) in contemporary practice, is associated with numerous side-effects(8, 
9). Specifically, these include declining bone health(10, 11), weight gain and 
metabolic syndrome(12), sexual dysfunction(13-15), hot flushes(16, 17), mental 
and cognitive decline(18-22), and physical deterioration and fatigue(23-26). 
LHRHa increase the risk of depression in men with PCa(27), reportedly driven by 
the loss of sexual function(28). Recent data suggest an increased risk of 
subsequent Alzheimer’s disease(29). An association with increased cardiac 
events is described but remains controversial(30).  Whereas a number of 
interventions have been demonstrated to ameliorate the toxicities of LHRHa to a 
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greater or lesser extent(8), further efforts are required to maintain the highest 
possible quality of life (QoL) for these patients. 
 
PATCH (Prostate Adenocarcinoma: TransCutaneous Hormones, MRC PR09) is 
an ongoing randomised controlled trial comparing transdermal oestradiol (tE2) 
delivered via transcutaneous patches versus LHRHa in men with advanced PCa. 
LHRHa act through the hypothalamic-pituitary axis to suppress testosterone 
production by the testes. Endogenous oestradiol (E2) in men is derived from 
testosterone through aromatase. Thus, it is also suppressed by, and 
consequently contributes to, the toxicity profile of LHRHa(9).  Exogenous 
administration of E2 inhibits the hypothalamic-pituitary axis (thereby suppressing 
testosterone)  as well but maintains oestradiol levels and hence mitigates some 
of the toxicity of LHRHa. Administration of exogenous  E2 via oral or intravenous 
routes is associated with risk of thrombosis and adverse cardiovascular (CVS) 
events(31). However, tE2 avoids the hepatic first-pass effects mediating these 
risks, as supported by previous results from PATCH (n=254) showing similar 
rates of CVS events in both tE2 and LHRHa arms after a median follow-up of 19 
months(32). Among this initial cohort, castration rates were similar in both arms.   
 
In this report, we compare QoL outcomes at 6 months from randomisation 
between the two hormonal treatments, based on data available from 
approximately 700 patients.  
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Methods 
Patients 
The study design for the PATCH trial has previously been described(32). Briefly, 
patients from participating UK centres were eligible for recruitment if they had 
locally advanced or metastatic PCa, and a treatment plan for indefinite ADT in 
the metastatic setting or ≥3 years for locally advanced disease. National 
regulatory and ethics committees approved the protocol, and participating 
hospitals obtained the appropriate local approvals. Participants provided written 
informed consent. 
 
Men were randomly allocated (in 2:1 ratio before February 2011 and then 1:1) to 
receive tE2 or LHRHa (open-label). This was done centrally according to a 
computer-based minimisation algorithm with a random element (80%), balanced 
for the following factors: disease stage, age, smoking status, personal or family 
history of heart disease, which LHRHa agent was to be used, PSA, intent to give 
radical radiotherapy, and centre. 
 
Patients in the tE2 arm received, after a dose regimen change in August 
2007(33), 4 FemSeven patches (100mcg/24hours), which were self-administered 
and changed twice weekly during the first 4 weeks. This was reduced to 3 
patches changed twice weekly, provided testosterone levels were <1.7 nmol/l. 
LHRHa was administered as per local practice. 
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Quality of life data collection 
Patients received a specific patient information sheet for the QoL study and 
provided separate consent to participate in this component of the study. QoL 
information was collected on paper questionnaires utilizing EORTC QLQ-C30 
and the prostate specific module QLQ-PR25. These were self-completed by 
participants, who were instructed to record responses without discussion with site 
staff, friends or relatives. Data were collected pre-randomisation, then at 4, 8 and 
12 weeks, and subsequently every 3 months up to 2 years post-randomisation. 
QLQ-C30 includes a range of domains which are either multi-item scales or 
single-item measures: a global health status/QoL scale, five function scales 
(physical, role, emotional, cognitive, and social), three symptom scales (fatigue, 
pain, and nausea and vomiting), and six single items (dyspnoea, insomnia, 
appetite loss, constipation, diarrhoea, and financial difficulties). QLQ-PR25 
contains 25 items designed to assess QoL in PCa patients, including urinary, 
bowel and sexual symptoms and functioning, and hormone-related symptoms. 
 
The Independent Data Monitoring Committee (IDMC) permitted release of the QoL 
data during the first 6 months from randomisation for patients already enrolled whilst 
the main trial continues.  
 
Statistical Analysis 
For each multi-item QoL domain (eg. global QoL), a summary score was derived 
according to the EORTC QLQ C-30 scoring manual(34), with range 0-100. For 
example, the summary global QoL score is a standardised average of the 
patients’ scores from the questions “How would you rate your overall health 
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during the past week?” and “How would you rate your overall quality of life?”. 
These scores were considered as continuous variables. A higher score 
corresponds to improved outcomes for global QoL and function scales, but 
indicates more symptoms (hence poorer outcomes) for symptoms scales. Single-
item domains (e.g. sexual interest) were analysed based on reported responses 
on the questionnaires (not at all, a little, quite a bit, or very much).  
 
The primary outcome was global QoL score at 6 months, as differences in 
hormone-related symptoms potentially impacting on QoL were expected to be 
apparent by then(17, 20, 25, 26, 32). The following domains were secondary 
outcomes: sexual interest, sexual activity, whether feeling less masculine as 
result of illness or treatment, cognitive functioning, physical functioning, fatigue, 
and selected hormone-related symptoms which were hot flushes, gynecomastia 
and weight gain. Gynecomastia was reported as sore or enlarged nipples or 
breasts. 
 
Patients were considered to have baseline QoL data, if they completed their first 
QoL questionnaire either by the date of randomisation or 1 week after, but before 
starting trial treatment. Information on QoL outcomes at 6 months was based on 
the questionnaire completed nearest to this time point, within  ±3 months window. 
Multi-item QoL domains at 6 months were compared between randomised arms 
using Tobit regression models (to account for scores being bounded by 0 and 
100)(35), adjusting for  baseline score. Single-item domains were categorised 
according to pre-defined binary outcomes for comparison between arms (for 
ease of clinical interpretation); for example, hot flushes were analysed as “quite a 
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bit”/“very much” versus “not at all”/“a little”. These were compared between arms 
using logistic regression models, adjusting for baseline response.  
 
All models were further adjusted for the following pre-defined baseline factors: 
age, calendar year (partly to account for the change in allocation ratio), smoking 
status, stage of disease (M0/M1), and whether patient was newly diagnosed or 
relapsing. All comparisons between arms were based on the original allocated 
treatment, and included patients randomised after the change in patch dose 
regimen(33) who had data on the relevant QoL domains at both baseline and 6 
months. A significance level of 0.05 was chosen a priori, without adjustment for 
multiple statistical testing. Additional exploratory analyses were undertaken to 
investigate associations between global QoL and other domains.  
 
Statistical analyses were performed using Stata version 14 (Stata Corporation, 
College Station, Texas, USA). 
 
Results 
Between 14 August 2007 and 5 October 2015, 875 men were recruited under the 
revised patch dose regime, 480 allocated to tE2 and 395 to LHRHa. Within the 
tE2 arm, 468 patients enrolled on the QoL sub-study, of whom 412 (86% of 480) 
completed QoL questionnaires at both baseline and 6 months. For the LHRHa 
group, 385 participated in the QoL sub study, with 315 (80% of 395) having both 
baseline and 6-month QoL data available (Figure 1). Baseline clinical 
characteristics were similar between arms for the 727 patients included in the 6-
month QoL analyses (Table 1). Overall median age was 74 years (interquartile 
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[IQR] range 68-79), median PSA 44 ng/ml (19-119), and 40% (294/727) had 
metastatic disease. There were no differences in baseline global QoL by age nor 
testosterone level, but men with T4 tumours had worse global QoL compared 
with other T-stages, and patients with metastatic disease had worse baseline 
QoL than M0 patients. 
 
Rates of castration were equivalent between the LHRHa and tE2 arms at both 3 and 
6 months; the proportion of patients with testosterone concentrations ≤1.7 nmol/l was 
93.6% for LHRHa and 93.7% for tE2 at 3 months, and 89.8% and 92.2% at 6 months 
respectively). 
 
At 6 months, global QoL declined from baseline in both arms (Table 2), but to a 
lesser extent in the tE2 patients (mean change -2.8) compared to those on 
LHRHa (-5.0). The estimated mean difference in 6-month global QoL between 
arms was +4.2 (95% confidence interval (CI) 1.2 to 7.1, p=0.006) in favour of tE2. 
There was no evidence that the treatment effect on global QoL at 6 months 
differed by age (≤70 versus >70 years); test for interaction p=0.56.  
 
In addition,  there was less decline in physical function among tE2 patients (mean 
change -2.8 vs -5.7), with mean difference in 6-month score +5.8 (2.8 to 8.8, 
p<0.001) between arms. In addition, tE2 patients had less fatigue at 6 months, 
mean difference between arms -4.3 (-8.1 to -0.6, p=0.02) favouring the patches. 
There was, however, no difference in reported decline in cognitive function 
between arms. 
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Analysis of specific domains linked with testosterone suppression (Table 3) 
showed that tE2 patients were less likely than LHRHa patients to report having 
no interest in sex (59% vs 74%, odds ratio [OR] 0.42 (95% CI 0.28 to 0.62, 
p<0.001)) and being “not at all” sexually active (78% vs 87%, OR 0.51 (0.32 to 
0.82, p=0.005)). Interestingly, there was weak evidence that the negative effect 
of LHRHa compared to tE2 on interest in sex was more pronounced in patients 
aged ≤70 years than those >70 years (t-test for interaction p=0.06). 
 
The likelihood of experiencing “quite a bit” or “very much” hot flushes was 
significantly lower in the tE2 group (8% vs 46%, OR 0.10 (0.07 to 0.16, 
p<0.001)). However, as expected, patients in the tE2 arm were much more likely 
to report “quite a bit” or “very much” gynecomastia than those receiving LHRHa 
(37% vs 5%, OR 12.70 (7.14 to 22.60, p<0.001)). There was no difference 
between arms in patients who reported feeling “quite a bit” or  “very much less” 
masculine (as a result of their illness or treatment) or experiencing “quite a bit” or 
“very much” weight gain. 
 
An association between hot flushes and deterioration in global QoL was 
observed in both arms at 6 months, with patients who experienced more severe 
symptoms reporting lower scores (Table 4, p<0.001). The relationship between 
gynecomastia and global QoL was assessed in the tE2 arm only, owing to few 
LHRHa patients reporting symptoms. Gynecomastia was associated with poorer 
global QoL at 6 months (Table 5, p=0.004), though the adverse effect was only 
seen in patients reporting “very much” gynecomastia (corresponding to 8% of the 
group with data available). Other QoL domains associated with lower global QoL 
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score were: poorer cognitive and physical function, increased fatigue, weight 
gain, and feeling less masculine (data not shown). 
  
After accounting for hot flushes, there was little difference in the 6-month global 
QoL score observed between arms (estimated mean difference -0.4 (95% CI -3.8 
to 3.0, p=0.80) comparing tE2 vs LHRHa patients). In comparison, the difference 
between arms remained after other QoL domains were individually adjusted for 
(data not shown). This suggests a significant component of the effect of 
treatment arm on global QoL could potentially be attributable to the higher 
incidence of hot flushes in LHRHa patients.  
 
In addition, there was an association between severity of hot flushes and fatigue 
at 6 months in both arms (data not shown), which may potentially account for the 
increased fatigue in the LHRHa versus tE2 arm; after adjusting for hot flushes, 
there was little difference in the 6-month fatigue score between arms (mean 
difference comparing tE2 vs LHRHa   0.0 (95% CI -4.3 to 4.4, p=0.98)). Further 
post-hoc analyses showed a relationship between hot flushes and sleep 
disturbance within both arms; 72% (124/172) of patients reporting “quite a bit” or 
“very much” hot flushes had trouble sleeping compared to 43% (232/534) of 
those with “not at all” or “a little” hot flushes (p<0.001, with similar results by arm). 
 
Patients experiencing gynecomastia were more likely to report feeling less 
masculine at 6 months, with 24% (36/148) of men who reported “quite a bit” or 
”very much” gynecomastia feeling “quite a bit” or ”very much” less masculine 
compared to 7% (17/247) of those reporting “not at all” or “a little” gynecomastia 
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(p<0.001). The protocol explicitly allowed prophylactic breast bud radiotherapy 
and 5% of patients on tE2 received this treatment as opposed to no patients on 
LHRHa.  Two patients underwent surgical treatment for gynaecomastia who were 
both on tE2, corresponding to 0.4% (2/480) of the overall tE2 arm cohort enrolled 
to date.  
 
Discussion 
In this study, we found better overall QoL after 6 months of androgen deprivation 
with tE2 compared to LHRHa, as well as less fatigue and improved physical 
function. While the magnitude of the QoL effects was modest(36), a number of 
additional differences are important to note. Men treated with LHRHa were more 
likely to report lack of sexual interest (74% vs 59%) and being not sexually active 
(87% vs 78%)[20]. In addition, tE2 patients had lower rates of hot flushes but more 
gynecomastia, consistent with earlier findings from the trial(32).  
Significant hot flushes were reported by 8% of men on tE2 compared to 44% of 
those on LHRHa. Interestingly, there was a suggestion that hot flushes mediated 
the treatment effect on global QoL, potentially accounting for both the reduced 
global QoL and increased fatigue in the LHRHa compared to tE2 arm. Conversely, 
37% men on tE2 reported significant gynecomastia compared with 5% on LHRHa, 
though gynecomastia was only seen to adversely affect global QoL if the patient 
reported “very much” symptoms (which corresponded to less than 10% of the tE2 
cohort). It is noteworthy that men may vary significantly in how bothersome 
gynecomastia is on an individual basis (37). In addition, data from the main 
PATCH trial suggest no association between oestradiol levels and clinical 
gynaecomastia (data not shown).  
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LHRHa therapy can severely impact on physical well-being and other QoL 
outcomes(15, 16, 27). Hot flushes, reported by 40-80% of men on LHRHa(17, 38, 
39), are linked to sleep disturbance and psychological distress(16, 39). In our 
study, patients with hot flushes had more trouble sleeping, which may account for 
the effect of hot flushes on increased fatigue and reduced QoL. tE2 appeared to 
be effective in reducing the severity of hot flushes in men on ADT in a prior study, 
consistent with our findings(40). The adverse effects of LHRHa on sexual 
outcomes, which can have significant psychological impact on both patients and 
their partners, have also been well-documented(13, 15, 27). Data from men 
castrated for reasons other than PCa suggest exogenous oestrogen can help 
maintain sexual interest(41, 42). Other potential benefits of tE2 reported include 
protective effects on cognition(43), though we did not find a difference in 
cognitive function between arms within our study, possibly because the short-
term outcomes analysed and/or limitations of the questionnaires used for 
assessing the cognitive domain.  
 
A number of strategies have been investigated in an attempt to mitigate the 
adverse effects LHRHa therapy(8). Randomised trials have demonstrated some 
benefit to medoxyprogesterone, venlafaxine and gabapentin in reducing hot 
flushes associated with LHRHa and exercise may improve levels of fatigue and 
overall QoL(44-46). Agents which can potentially preserve bone health during 
treatment with LHRHa include bisphosphonates, denosumab or toremifine(8). 
Importantly however, data from PATCH recently showed that patients on tE2 
avoid the loss in bone mineral density seen with LHRHa administration(47). The 
data presented here suggest tE2 as an alternative to LHRHa might limit the 
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requirement for additional treatments to allay the side-effects of LHRHa over and 
above bone health. Alternatively a low dose of tE2 in addition to LHRHa could be 
investigated in the future as a treatment for bothersome hot flushes. 
 
Alternatively, an intermittent approach to ADT has been assessed for clinical 
efficacy and potential QoL benefits. In the non-metastatic setting, intermittent 
ADT appears to be non-inferior to continuous therapy in terms of overall survival, 
with some potential benefits with respect to hot flushes, libido and possibly 
fatigue, but not global health(48). However, a randomised trial by Hussain et al. 
including 1535 men with metastatic PCa failed to show non-inferiority for 
intermittent ADT based on overall survival. Although small improvements were 
initially observed for sexual function and mental health(49), older men assigned 
to intermittent ADT had no apparent reduction in bone, endocrine, or cognitive 
events and experienced an increased incidence of ischemic and thrombotic 
events(50).  
 
It is increasingly apparent across a number of QoL domains that there are 
important differences in the unintended consequences of  ADT depending upon 
the method chosen to achieve castrate levels of testosterone(51, 52). Here, we 
have shown that at 6 months of treatment, tE2 improves patients’ QoL in a 
number of domains compared to LHRH— i.e. fewer hot flushes, less fatigue, 
improved physical functioning, sexual interest and sexual activity— but at a cost 
of increased incidences of gynecomastia. This can be viewed in addition to the 
beneficial effects on tE2 on bone mineral density previously reported within 
PATCH (47), also noting the lack of any excess cardiovascular or 
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thromboembolic effects from tE2 (32). From our data, hot flushes appear to 
potentially account for the increased fatigue and reduced global QoL among 
patients on LHRHa.  
 
We acknowledge the relatively short-term outcomes assessed and presented 
here. However, ADT is often used for periods as short as 6 months when 
administered as neoadjuvant therapy along with radiotherapy to treat localised 
disease. As such, our 6 months QoL data are clinically pertinent, given short-term 
neoadjuvant ADT has been shown to be associated with impaired QoL(53). 
Further data from the ongoing trial will inform whether the differences between 
arms persist long term. Although it is premature to suggest a fundamental 
change in practice when it comes to starting patients on ADT, comprehensive 
analysis of comparative efficacy and toxicity within PATCH will allow men and 
their partners to optimise treatment choices.  
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Figure 1: CONSORT diagram of patient inclusion in the analysis of 6-month quality of 
life data 
 
Abbreviations: QoL, quality of life; LHRHa, LHRH agonists; tE2, transdermal oestradiol. 
a  The allocation ratio was 1:2 LHRHa: tE2 before 21/02/2011 and 1:1 thereafter. 
b  Patients were considered to have baseline QoL data if they had completed their first  
QoL questionnaire either by the date of randomisation or within 1 week after but before 
starting trial treatment. 
c Since overall survival is a co-primary outcome measure in the ongoing trial, the number 
of patients who have died before completing 6-month QoL questionnaire is not provided.  
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Table 1: Patient characteristics for those with both baseline and 6-month quality of life 
questionnaires completed (N=727) 
 LHRHa 
(n=315) 
tE2 (n=412) 
Age at randomisation (years)   
<70   99 (31%)  128 (31%)  
    70-79 146 (46%)  202 (49%)  
    ≥80   70 (22%)    82 (20%)  
    Median (IQR) 74 (67-79) 73 (68-79) 
Metastatic disease 133 (42%)  161 (39%)  
Bone metastases (% of those with metastatic 
disease) 
120 (90%) 148 (92%) 
PSA concentration (ng/ml)   
<50 173 (55%)  214 (52%)  
   50-<500 121 (39%)  163 (40%)  
    ≥500   19 (6%)     35 (9%)   
   Median (IQR) 43 (22-115) 45 (18-119) 
Tumour status   
    T0/1/2   19 (6%)     27 (7%)   
    T3 220 (70%)  296 (72%)  
    T4   52 (17%)    64 (16%)  
    TX   24 (8%)     25 (6%)   
N category   
    N0 118 (37%)  145 (35%)  
    N+   87 (28%)  102 (25%)  
    NX 110 (35%)  165 (40%)  
Gleason sum score   
    4-6   28 (10%)    28 (8%)   
    7   89 (31%)  137 (37%)  
    8-10 171 (59%)  207 (56%)  
Smoking status   
   Never smoked 119 (38%)  167 (41%)  
   Previous smoker 162 (51%)  204 (50%)  
   Current smoker   34 (11%)    41 (10%)  
WHO performance status   
   Normal activity  209 (66%)  293 (71%)  
   Avoid strenuous activity   92 (29%)  102 (25%)  
   Up and about >50%    14 (4%)     17 (4%)   
Year of randomisation   
   2007/08   30 (10%)    69 (17%)  
   2009/10   40 (13%)    75 (18%)  
   2011/12 141 (45%)  156 (38%)  
 2013/15 104 (33%)  112 (27%)  
Abbreviations: LHRHa, LHRH agonists; tE2, transdermal oestradiol; IQR, interquartile 
range 
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Table 2:   Quality of life multi-item domains: scores at 6 months by treatment arma 
Outcome  Arm 
Number of 
patients 
Mean score at 
baseline  
(95% CI) 
Mean score at  
6-month  
 (95% CI) 
Mean change in  
6-month score from 
baseline 
(95% CI) 
Mean difference 
in 6-month 
score between 
arms  (95% CI) 
P-value 
comparing 
arms 
        
Global QoL score LHRHa 308 75.1  (72.7,77.4) 70.1  (67.7,72.4) -5.0  (-7.4,-2.7)    
 tE2 403 78.0  (76.1,80.0) 75.2  (73.3,77.2) -2.8  (-4.7,-0.8)  +4.2 (1.2,7.1)   0.006 
        
Cognitive function LHRHa 309 86.9  (84.8,89.0) 82.8  (80.7,84.9) -4.1  (-6.2,-2.0)    
 tE2 403 87.5  (85.7,89.3) 84.0  (82.2,85.9) -3.5  (-5.3,-1.6)  +1.9 (-1.8,5.5)  0.32 
        
Physical function LHRHa 307 87.6  (85.4,89.8) 81.8  (79.6,84.1) -5.7  (-7.9,-3.5)    
 tE2 399 89.0  (87.2,90.9) 86.2  (84.3,88.1) -2.8  (-4.7,-1.0)  +5.8 (2.8,8.8)   <0.001 
        
Fatigue LHRHa 304 18.9  (16.4,21.4) 27.2  (24.7,29.7)  8.3  (5.8,10.8)     
 tE2 400 17.1  (14.8,19.4) 23.0  (20.8,25.3)  6.0  (3.7,8.2)    -4.3 (-8.1,-0.6) 0.02 
        
Abbreviations: QoL, quality of life; LHRHa, LHRH agonists; tE2, transdermal oestradiol; CI, confidence interval. 
a  For global QoL, cognitive function and physical function, a higher score corresponds to a better outcome. For fatigue, a higher score 
corresponds to more fatigue. 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Table 3:   Quality of life single item domains: proportion of patients with pre-defined outcomes at 6-months by treatment arm 
Outcome Arm Number 
of 
patients 
Number (%) of 
patients with 
outcome at baseline 
Number (%) of 
patients with outcome 
at 6 months 
Odds ratio 
(95% CI) 
P-value 
comparing 
arms 
       
Felt quite a bit/very much less masculine  LHRHa 292          16 (5%)          41 (14%)   
 tE2 381          18 (5%)          53 (14%) 0.92 (0.57,1.48) 0.73 
       
Not at all interested in sex  LHRHa 268        118 (44%)        199 (74%)   
 tE2 350        155 (44%)        208 (59%) 0.42 (0.28,0.62) <0.001 
       
Not at all sexually active  LHRHa 266        168 (63%)        231 (87%)   
 tE2 348        214 (61%)        271 (78%) 0.51 (0.32,0.82) 0.005 
       
Quite a bit/very much gynecomastia  LHRHa 293            4 (1%)         14 (5%)   
 tE2 386            2 (1%)       144 (37%) 12.70 (7.14,22.60) <0.001 
       
Quite a bit/very much hot flushes  LHRHa 291            6 (2%)       135 (46%)   
 tE2 390            9 (2%)         32 (8%) 0.10 (0.07,0.16) <0.001 
       
Quite a bit/very much weight gain  LHRHa 296         13 (4%)         21 (7%)  . 
 tE2 379         13 (3%)         27 (7%) 1.06 (0.56,2.00) 0.87 
       
Abbreviations: LHRHa, LHRH agonists; tE2, transdermal oestradiol; CI, confidence interval. 
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Table 4: Global quality of life score at 6 months in both treatment arms, by patients’ experience of hot flushes. 
 LHRHa arm tE2 arm  
Mean difference in 
6-month score  
(95% CI), both arms 
combineda 
Whether 
experienced 
hot flushes at 
6 months 
 
Number of 
patients 
(% of total) 
 
Mean score at 
6 months 
(95% CI) 
Mean change in 
6-month score 
from baseline 
(95% CI) 
Number of 
patients 
(% of total) 
 
Mean score at 
6 months 
(95% CI) 
Mean change in 
6-month score 
from baseline 
(95% CI) 
        
Not at all     77 (26%) 75.1 (70.4,79.8) -0.9 (-5.6,3.9)     288 (73%) 78.6 (76.4,80.8) -1.8 (-4.0,0.4)       Reference group           
A little     83 (28%) 74.0 (69.9,78.1) -4.0 (-8.1,0.1)       75 (19%) 65.1 (60.6,69.6) -5.9 (-10.4,-1.4)     -6.8 (-10.6,-3.1) 
Quite a bit     92 (31%) 65.6 (61.1,70.1) -8.1 (-12.6,-3.5)     23 (6%) 67.4 (58.0,76.7) -5.8 (-15.1,3.6)     -10.4 (-15.0,-5.9) 
Very much     47 (16%) 62.4 (56.6,68.2) -7.6 (-13.4,-1.9)     10 (3%) 65.0 (52.7,77.4) -2.5 (-14.8,9.9)     -11.8 (-17.6,-6.0) 
        
            P-value <0.001 
        
Abbreviations: LHRHa, LHRH agonists; tE2, transdermal oestradiol; CI, confidence interval. 
a Estimated from Tobit regression models, adjusted for treatment arms, baseline global quality of life score and other pre-defined baseline 
factors. There was no evidence that the effect of hot flushes on 6-month global quality of life score differed by treatment arm (p for 
interaction=0.20).  
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Table 5: Global  quality of life score at 6 months in the tE2 arm, by whether patient reported to have experienced gynecomastiaa 
Whether 
experienced sore 
or enlarged 
nipples or breasts 
Number of 
patients 
(% of total) 
Mean score 
at baseline 
(95% CI) 
Mean score 
at 6 months 
(95% CI) 
Mean change in 
6-month score 
from baseline 
(95% CI) 
Mean difference 
in 6-month 
scoreb 
(95% CI) 
      
Not at all      55 (14%) 78.6  (73.0,84.3) 73.3  (67.9,78.7) -5.3  (-10.7,0.1)  Reference group           
A little    190 (49%) 80.0  (77.2,82.7) 78.0  (75.2,80.9) -1.9  (-4.8,0.9)    4.8 (-0.8,10.4) 
Quite a bit    114 (29%) 74.4  (70.9,78.0) 73.8  (70.5,77.0) -0.7  (-3.9,2.6)    3.3 (-2.7,9.3)  
Very much      32 (8%)  74.5  (66.7,82.2) 63.8  (56.1,71.5) -10.7  (-18.4,-3.0) -7.6 (-15.6,0.4) 
      
     P-value= 0.004 
      
Abbreviations: CI, confidence interval 
a This association was not assessed in the LHRHa arm owing to few patients reporting symptoms. 
b Estimated from Tobit regression models, adjusted for baseline global quality of life score and other pre-defined baseline factors. 
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